Satish Narayan, MD
Psychiatry · Plano, TXNPI 1194787200
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.0%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Johnson & Johnson at 46.2% of the total. Reporting peaked in 2022 at $10,253 and has fallen 76.1% since, to $2,455 in 2025. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 845 payments — averaging $25.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$10K
- Teva Pharmaceuticals USA, Inc.$3K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- AbbVie$933
- Sunovion Pharmaceuticals Inc.$843
- plus $5K from 34 others
Across 34 payments — averaging $2214.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$75K
What the payments were for
- Consulting fees$8,10038%
- Speaking & faculty fees$1,0505%
- Travel & lodging$6383%
- Food & beverage$11,39253%
- Education$3232%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$9,232
- AUSTEDO$1,050
- ARISTADA$494
- SUBLOCADE$123
- ARISTADA INITIO$123
How this compares
$21,503 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 43 | $422,480 |
| SpravatoEsketamine Hcl | 231 | $286,394 |
| AustedoDeutetrabenazine | 26 | $243,213 |
| AuvelityDextromethorphan Hbr/Bupropion | 70 | $77,774 |
| Invega SustennaPaliperidone Palmitate | 17 | $51,516 |
| RexultiBrexpiprazole | 14 | $46,076 |
| BelsomraSuvorexant | 61 | $26,271 |
| CaplytaLumateperone Tosylate | 14 | $23,234 |
| VraylarCariprazine Hcl | 12 | $18,661 |
| TrintellixVortioxetine Hydrobromide | 31 | $15,450 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 181 | $6,950 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 94 | $6,756 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 58 | $6,408 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $5,386 |
| Aripiprazole | 101 | $3,137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $2,548 | $665,69469 claims |
| Johnson & JohnsonSpravato, Invega Sustenna | $9,936 | $337,910248 claims |
| Axsome Therapeutics, Inc.Auvelity | $194 | $77,77470 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,256 | $46,07614 claims |
| MerckBelsomra | $66 | $26,27161 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $559 | $23,23414 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $537 | $20,83646 claims |
| AbbVieVraylar | $933 | $18,66112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Plano
- Suresh SureddiPlano$2.2M
- David CrumpackerPlano$386K
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.